

Jiaxin Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3192170/publications.pdf>

Version: 2024-02-01

54
papers

863
citations

686830

13
h-index

580395

25
g-index

74
all docs

74
docs citations

74
times ranked

1383
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	0.9	185
2	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. <i>Clinical Infectious Diseases</i> , 2022, 74, 734-742.	2.9	88
3	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	0.8	52
4	Case Fatality Risk of the First Pandemic Wave of Coronavirus Disease 2019 (COVID-19) in China. <i>Clinical Infectious Diseases</i> , 2021, 73, e79-e85.	2.9	50
5	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020, 11, 799-804.	0.8	24
6	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 2472-2477.	0.9	20
7	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	0.8	19
8	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. <i>Arthritis Research and Therapy</i> , 2019, 21, 44.	1.6	18
9	Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 255.	1.6	18
10	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1479-1488.	0.9	17
11	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 488-492.	0.8	17
12	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 178-185.	0.7	17
13	Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients. <i>Rheumatology</i> , 2021, 60, 2635-2646.	0.9	16
14	The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	0.9	14
15	The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 418-426.	4.6	14
16	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 21.	1.6	14
17	Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet's disease: a single-centre experience in China. <i>Rheumatology</i> , 2018, 57, 2057-2059.	0.9	13
18	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020, 11, 3047-3052.	0.8	13

#	ARTICLE	IF	CITATIONS
19	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 171-175.	0.4	13
20	Effectiveness and safety of interferon β 2a as an add-on treatment for refractory Behçet's uveitis. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984788.	1.1	12
21	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. <i>Frontiers in Medicine</i> , 2020, 7, 583944.	1.2	12
22	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	0.8	10
23	Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 102.	1.6	10
24	Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. <i>Emerging Microbes and Infections</i> , 2021, 10, 2303-2312.	3.0	10
25	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020, 11, 475-480.	0.8	9
26	Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans. <i>Journal of Infection</i> , 2020, 80, 310-319.	1.7	9
27	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110005.	1.0	9
28	The Clinical Features and Risk Factors of Parenchymal Neuro-Behçet's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	0.9	8
29	Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences. <i>Clinical Rheumatology</i> , 2020, 39, 3449-3454.	1.0	8
30	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	0.8	8
31	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 152.	1.2	8
32	Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019. <i>EBioMedicine</i> , 2021, 68, 103398.	2.7	8
33	Characteristics and Outcomes of Coronary Artery Involvement in Polyarteritis Nodosa. <i>Canadian Journal of Cardiology</i> , 2021, 37, 895-903.	0.8	8
34	Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2021, 12, 747076.	2.2	7
35	Systemic lupus erythematosus gastrointestinal involvement: a computed tomography-based assessment. <i>Scientific Reports</i> , 2020, 10, 6400.	1.6	6
36	Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage. <i>Journal of Autoimmunity</i> , 2021, 122, 102650.	3.0	6

#	ARTICLE	IF	CITATIONS
37	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020, 11, 829-834.	0.8	5
38	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020, 11, 1099-1104.	0.8	5
39	The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease. <i>Rheumatology</i> , 2022, 61, 815-825.	0.9	5
40	Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort. <i>Frontiers in Medicine</i> , 2021, 8, 784520.	1.2	5
41	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. <i>Clinical Rheumatology</i> , 2021, 40, 4589-4596.	1.0	4
42	UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease. <i>Rheumatology</i> , 2021, 60, 3252-3261.	0.9	4
43	Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1194-1200.	0.9	3
44	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021, 12, 580271.	2.2	3
45	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease. <i>Rheumatology</i> , 2022, 61, 2197-2209.	0.9	3
46	SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 1841-1848.	0.9	3
47	Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. <i>BMC Ophthalmology</i> , 2021, 21, 447.	0.6	3
48	Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up. <i>Journal of Internal Medicine</i> , 2022, 292, 91-102.	2.7	3
49	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 198-202.	0.8	2
50	Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	2
51	Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome. <i>Rheumatology</i> , 2022, 61, e277-e279.	0.9	2
52	The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	2
53	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. <i>International Journal of Clinical Practice</i> , 2021, 75, e13819.	0.8	1
54	Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobulin G4-related disease. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	0.9	0